Clearside Biomedical is now in post-effective-date administration: the first amended combined disclosure statement and Chapter 11 plan has been confirmed, and the claims agent has distributed the confirmation-and-effective-date noticeDkt. 468. The remaining case activity is therefore centered on implementing the plan, resolving administrative matters and professional compensation, rather than pursuing a new restructuring transaction.
The ophthalmology-focused biopharmaceutical company filed Chapter 11 on November 23, 2025, after sustained operating losses and a deteriorating cash runway left it unable to fund development and commercialization without a strategic transaction. Its first-day declarationDkt. 2 reported approximately $3.0 million of unencumbered cash and no funded or outstanding trade debt, but described substantial accumulated losses and a royalty-monetization structure under which HealthCare Royalty Management held rights to certain royalties and milestones and a pledge of the equity in a nondebtor royalty subsidiary. Before filing, Clearside and its advisers canvassed strategic and financing alternatives—contacting 41 prospective buyers and meeting with 71 potential investors—but did not secure sufficient new capital. A September 2025 amendment with HealthCare Royalty provided $3 million of additional consideration and contemplated a possible stalking-horse bid, supplying liquidity while the company prepared for court-supervised relief.
Clearside entered Chapter 11 intending to run an expedited section 363 sale of substantially all assets, including its SCS Microinjector platform, XIPERE-related interests, clinical pipeline and patent portfolio, while using unencumbered cash to fund the case. The process ultimately shifted from that initial sale posture to the confirmed plan now in effect; the permitted record does not establish the plan’s distribution mechanics or the disposition of individual assets. Near-term docket activity is administrative: for example, lead counsel’s fifth monthly fee applicationDkt. 469 carries an August 10, 2026 objection deadline, while the confirmation-and-effective-date notice also addresses the final deadline for administrative expense claims.
